Eli Lilly

German researchers found that COVID-19 therapies developed by Eli Lilly and Regeneron lose most of their effectiveness when exposed in laboratory tests to the Omicron variant of coronavirus, likely reducing treatment options if the new variant prevails.

Regeneron Pharmaceuticals Inc. said on November 8 a single dose of the company’s antibody cocktail reduced the risk of contracting Covid-19 by 81.6 percent in a late-stage trial, in the two to eight months period following the drug’s administration.

Sanofi

Dupixent (dupilumab) scored the blockbuster medicine’s second study win in a week after Regeneron Pharmaceuticals and Sanofi revealed positive results from the second Phase III trial for the treatment of eosinophilic esophagitis (EoE). 

Nearly four months after Intellia Therapeutics – along with partner Regeneron Pharmaceuticals – reinvigorated the CRISPR space with the first-ever clinical evidence that CRISPR gene editing inside the body can be safe and effective, the asset in question was granted Orphan Drug Designation by the U.S. Food and Drug Administration.

The U.S. Food and Drug Administration agreed to place Regeneron Pharmaceuticals Inc.’s Biologics License Application (BLA) for the Covid-19 drug REGEN-COV under priority review with a target action date of April 13, 2022.

A study out of Oxford University’s Leverhulme Centre for Demographic Science found that the Covid-19 pandemic has resulted in the largest drop in life expectancy in western Europe since World War II.

A World Health Organization (WHO) panel on Sept. 24 recommended the use of Regeneron and Roche’s Covid-19 antibody cocktail for patients at high risk of hospitalizations and those severely ill with no natural antibodies.

Companies presented very promising data for treating lung cancer at European Society of Medical Oncology (ESMO) Congress 2021.

Eli Lilly

Eli Lilly said on Sept. 15 the U.S. government bought 388,000 additional doses of the company’s Covid-19 antibody therapy and Regeneron Pharmaceuticals said on Sept. 14 the U.S. government was buying 1.4 million additional doses of the Covid-19 antibody cocktail REGEN-COV., as infections surge due to the fast-spreading Delta variant.

Pfizer Inc.’s experimental drug to treat patients with moderate-to-severe atopic dermatitis met the main goals of improving symptoms in adult patients compared to a rival treatment from Regeneron Pharmaceutical Inc.